FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097373074> ?p ?o ?g. }

• W2097373074 endingPage "1117" @default.
• W2097373074 startingPage "1109" @default.
• W2097373074 abstract "ObjectiveProteomic analysis could improve our understanding of the mechanisms and consequences of myeloproliferation. Healthy subjects treated with granulocyte colony-stimulating factor (G-CSF) were used as a model of myeloproliferation.MethodsLevels of 80 soluble factors were measured by enzyme-linked immunosorbent assay before and after 5 days of G-CSF. Both serum and plasma levels were measured to generate a comprehensive profile and determine whether serum or plasma best portrays biological and physiological changes.ResultsComparison of samples collected prior to G-CSF demonstrated that 44 factors differed between serum and plasma. Concentrations of several growth factors and chemokines were greater in serum than in plasma, while the opposite was true for several interleukins. Following G-CSF serum levels of 14 factors and plasma levels of 15 factors changed. Eleven increased in both serum and plasma, including cell adhesion molecules (vascular cell adhesion molecule-1, E-selectin, and L-selectin), matrix metalloproteases (MMP-1, -8, and -13), cytokine receptors (tumor necrosis factor receptor 1 and 2, and interleukin-2 receptor), the acute phase reactant, serum amyloid A, and a growth factor, hepatocyte growth factor.ConclusionSome protein levels differ markedly in serum and plasma. Myeloproliferation is associated with changes in the levels of several proteases, adhesion molecules, and cytokines. Proteomic analysis could improve our understanding of the mechanisms and consequences of myeloproliferation. Healthy subjects treated with granulocyte colony-stimulating factor (G-CSF) were used as a model of myeloproliferation. Levels of 80 soluble factors were measured by enzyme-linked immunosorbent assay before and after 5 days of G-CSF. Both serum and plasma levels were measured to generate a comprehensive profile and determine whether serum or plasma best portrays biological and physiological changes. Comparison of samples collected prior to G-CSF demonstrated that 44 factors differed between serum and plasma. Concentrations of several growth factors and chemokines were greater in serum than in plasma, while the opposite was true for several interleukins. Following G-CSF serum levels of 14 factors and plasma levels of 15 factors changed. Eleven increased in both serum and plasma, including cell adhesion molecules (vascular cell adhesion molecule-1, E-selectin, and L-selectin), matrix metalloproteases (MMP-1, -8, and -13), cytokine receptors (tumor necrosis factor receptor 1 and 2, and interleukin-2 receptor), the acute phase reactant, serum amyloid A, and a growth factor, hepatocyte growth factor. Some protein levels differ markedly in serum and plasma. Myeloproliferation is associated with changes in the levels of several proteases, adhesion molecules, and cytokines." @default.
• W2097373074 created "2016-06-24" @default.
• W2097373074 creator A5001134935 @default.
• W2097373074 creator A5022506509 @default.
• W2097373074 creator A5059941996 @default.
• W2097373074 creator A5069456738 @default.
• W2097373074 creator A5070570250 @default.
• W2097373074 creator A5072166479 @default.
• W2097373074 creator A5080740261 @default.
• W2097373074 creator A5087049535 @default.
• W2097373074 date "2005-10-01" @default.
• W2097373074 modified "2023-09-30" @default.
• W2097373074 title "Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor" @default.
• W2097373074 cites W190201512 @default.
• W2097373074 cites W1964825686 @default.
• W2097373074 cites W1973599137 @default.
• W2097373074 cites W1978172024 @default.
• W2097373074 cites W1979278422 @default.
• W2097373074 cites W1985787114 @default.
• W2097373074 cites W1986410924 @default.
• W2097373074 cites W1987968353 @default.
• W2097373074 cites W2004814040 @default.
• W2097373074 cites W2024158539 @default.
• W2097373074 cites W2037315239 @default.
• W2097373074 cites W2047120129 @default.
• W2097373074 cites W2048360052 @default.
• W2097373074 cites W2051206141 @default.
• W2097373074 cites W2055438217 @default.
• W2097373074 cites W2070619903 @default.
• W2097373074 cites W2073004682 @default.
• W2097373074 cites W2087813315 @default.
• W2097373074 cites W2089460049 @default.
• W2097373074 cites W2092322810 @default.
• W2097373074 cites W2101500053 @default.
• W2097373074 cites W2118168943 @default.
• W2097373074 cites W2127760302 @default.
• W2097373074 cites W2128380267 @default.
• W2097373074 cites W2131055846 @default.
• W2097373074 cites W2150045726 @default.
• W2097373074 cites W2150926065 @default.
• W2097373074 cites W2240289126 @default.
• W2097373074 cites W2255700465 @default.
• W2097373074 cites W2405778328 @default.
• W2097373074 cites W2409201598 @default.
• W2097373074 cites W2417849984 @default.
• W2097373074 cites W324624459 @default.
• W2097373074 cites W4234772783 @default.
• W2097373074 cites W2129465945 @default.
• W2097373074 doi "https://doi.org/10.1016/j.exphem.2005.06.029" @default.
• W2097373074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16219533" @default.
• W2097373074 hasPublicationYear "2005" @default.
• W2097373074 type Work @default.
• W2097373074 sameAs 2097373074 @default.
• W2097373074 citedByCount "13" @default.
• W2097373074 countsByYear W20973730742012 @default.
• W2097373074 countsByYear W20973730742016 @default.
• W2097373074 countsByYear W20973730742017 @default.
• W2097373074 crossrefType "journal-article" @default.
• W2097373074 hasAuthorship W2097373074A5001134935 @default.
• W2097373074 hasAuthorship W2097373074A5022506509 @default.
• W2097373074 hasAuthorship W2097373074A5059941996 @default.
• W2097373074 hasAuthorship W2097373074A5069456738 @default.
• W2097373074 hasAuthorship W2097373074A5070570250 @default.
• W2097373074 hasAuthorship W2097373074A5072166479 @default.
• W2097373074 hasAuthorship W2097373074A5080740261 @default.
• W2097373074 hasAuthorship W2097373074A5087049535 @default.
• W2097373074 hasBestOaLocation W20973730741 @default.
• W2097373074 hasConcept C126322002 @default.
• W2097373074 hasConcept C13373296 @default.
• W2097373074 hasConcept C134018914 @default.
• W2097373074 hasConcept C170493617 @default.
• W2097373074 hasConcept C17991360 @default.
• W2097373074 hasConcept C203014093 @default.
• W2097373074 hasConcept C2776694085 @default.
• W2097373074 hasConcept C2776914184 @default.
• W2097373074 hasConcept C2777767877 @default.
• W2097373074 hasConcept C2777802486 @default.
• W2097373074 hasConcept C2777983669 @default.
• W2097373074 hasConcept C2778690821 @default.
• W2097373074 hasConcept C55359608 @default.
• W2097373074 hasConcept C71924100 @default.
• W2097373074 hasConcept C86803240 @default.
• W2097373074 hasConceptScore W2097373074C126322002 @default.
• W2097373074 hasConceptScore W2097373074C13373296 @default.
• W2097373074 hasConceptScore W2097373074C134018914 @default.
• W2097373074 hasConceptScore W2097373074C170493617 @default.
• W2097373074 hasConceptScore W2097373074C17991360 @default.
• W2097373074 hasConceptScore W2097373074C203014093 @default.
• W2097373074 hasConceptScore W2097373074C2776694085 @default.
• W2097373074 hasConceptScore W2097373074C2776914184 @default.
• W2097373074 hasConceptScore W2097373074C2777767877 @default.
• W2097373074 hasConceptScore W2097373074C2777802486 @default.
• W2097373074 hasConceptScore W2097373074C2777983669 @default.
• W2097373074 hasConceptScore W2097373074C2778690821 @default.
• W2097373074 hasConceptScore W2097373074C55359608 @default.
• W2097373074 hasConceptScore W2097373074C71924100 @default.
• W2097373074 hasConceptScore W2097373074C86803240 @default.
• W2097373074 hasIssue "10" @default.

• next